Generex Biotechnology Corporation Intends To Acquire Medisource Partners

Creative Commons License Source:  ID 12019 , no changes made.
Advertisement

Generex Biotechnology Corporation has announced that the company has entered into a letter of intent (LOI) to acquire Medisource Partners.

Founded in 1983, Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies, headquartered in Miramar, Florida, USA, with offices in Burlington, Ontario, Canada. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in a Medical Services Organization (MSO) network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Medisource Partners, founded 10 years ago, based in Dallas, Texas, USA, is an FDA-registered distributor of medical and surgical products including bone grafts and biologics from a range of surgical product manufacturers. The company is currently contracted with over 25 vendors (including Pantheon Medical) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, and stem cells), durable medical equipment, and soft goods. The company also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery.

Under the terms of the deal, Generex will acquire all of the assets of Medisource including business operations, accounts receivable and inventory, contracts, and real estate, on a debt free basis, for One Million Dollars ($1,000,000) worth of Generex (GNBT) stock, plus additional cash and stock consideration for achieving certain sales and profit projections.

Advertisement

“MediSource Partners was founded in 2009 and designed to be unique amongst its competitors by operating as a service-focused, ‘one stop shop’ for the healthcare professionals it serves. With over 25,000 products in its catalogue, including thirteen (13) lines dedicated to spine, Medisource prides itself on its ability to service everything from small private practices across several disciplines, to entire hospital systems. The large and broad-based inventory allows our client physicians to ‘customize’ their operating environment by selecting and implementing the hardware, biologics, soft goods and ancillary tools they feel most confident in and comfortable with. In addition, the ‘one stop shop’ model reduces the burden placed on support staff tasked with managing multiple reps from multiple vendors and shortens the distribution chain to reduce costs and potential redundancies. The success of this model is demonstrated in Medisource’s ability to offer this client-focused, low-impact service at a pricing matrix often below even standard GPO pricing, thus increasing client profitability and productivity.” – Travis H. Bird, CEO of Medisource

“The strategic acquisition of Medisource Partners provides Generex with a value-added service model that fits the corporate mission of NuGenerex Distribution Solutions, adding immediate revenues and profits, while providing significant upside as we integrate the medical and surgical supply business into our current and future MSO networks,” … “The extensive lines of surgical and biological products offered in the Medisource catalogue will enable us to expand our offerings to now include hospital systems, as well as our MSO partners. Our management services will not only integrate purchasing and billing, but will provide better pricing and access to new products, especially biologics, including platelet rich plasma, bone marrow aspirate, cord blood, and bone implants. We are excited that the acquisition of Medisource will provide access to a whole new line of products that not only enhances our current MSO network in the five states, but will eventually support the expansion of our MSO network into 27 states. We are in the process of completing the due diligence on this acquisition, with plans to close the transaction in the coming weeks.” – Joe Moscato, CEO of Generex

Sources:

  1. https://www.businesswire.com/news/home/20190110005211/en/Generex-Biotechnology-Announces-Acquisition-Surgical-Supply-Distribution
  2. https://www.crunchbase.com/organization/generex-biotechnology#section-overview
  3. https://www.crunchbase.com/organization/medisource-partners#section-overview
Advertisement

David is a consultant/medical writer for a number of ongoing healthcare initiatives including for Athla LLC/ HealthLabs, a discovery automation company for Big Data leveraging Big Compute. He has a number of years experience in academic R&D and healthcare related projects including the fields of oncology and immunotherapy.